@prefix ns1: <http://linked.opendata.cz/ontology/drug-encyclopedia/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix xml: <http://www.w3.org/XML/1998/namespace> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<http://linked.opendata.cz/resource/ATC/L01BC01> a ns1:ATCConcept ;
    skos:notation "L01BC01" ;
    skos:prefLabel "Cytarabin"@cs,
        "Cytarabine"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0005564> a ns1:Ingredient ;
    ns1:contraindicatedWith "http://linked.opendata.cz/resource/ndfrt/disease/N0000000999",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000010195" ;
    ns1:description "A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)     "@en ;
    ns1:hasMechanismOfAction "http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000233" ;
    ns1:hasMedicinalProduct "http://linked.opendata.cz/resource/sukl/medicinal-product/ALEXAN-50-MG-ML",
        "http://linked.opendata.cz/resource/sukl/medicinal-product/CYTARABIN-KABI-100-MG-ML",
        "http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-1-G",
        "http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-100-MG",
        "http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-500-MG",
        "http://linked.opendata.cz/resource/sukl/medicinal-product/DEPOCYTE-50-MG" ;
    ns1:hasPharmacologicalAction "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001471",
        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001518",
        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0011171" ;
    ns1:hasPhysiologicEffect "http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000008576" ;
    ns1:hasPregnancyCategory "http://linked.opendata.cz/resource/fda-spl/pregnancy-category/D" ;
    ns1:mayTreat "http://linked.opendata.cz/resource/ndfrt/disease/N0000000566",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000001815",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000001905",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000001978",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000003261",
        "http://linked.opendata.cz/resource/ndfrt/disease/N0000003565" ;
    ns1:title "Cytarabin"@cs,
        "Cytarabine"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001471> a ns1:PharmacologicalAction ;
    ns1:description "Antimetabolites that are useful in cancer chemotherapy.     "@en ;
    ns1:title "Antimetabolity antitumorózní"@cs,
        "Antimetabolites, antineoplastic"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001518> a ns1:PharmacologicalAction ;
    ns1:description "Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.     "@en ;
    ns1:title "Antivirové látky"@cs,
        "Antiviral agents"@en .

<http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0011171> a ns1:PharmacologicalAction ;
    ns1:description "Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.     "@en ;
    ns1:title "Imunosupresiva"@cs,
        "Immunosuppressive agents"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000000566> a ns1:DiseaseOrFinding ;
    ns1:description "An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.     "@en ;
    ns1:title "Blastická krize"@cs,
        "Blast crisis"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000000999> a ns1:DiseaseOrFinding ;
    ns1:description "Immunologically mediated adverse reactions to medicinal substances used legally or illegally.     "@en ;
    ns1:title "Léková alergie"@cs,
        "Drug hypersensitivity"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000001815> a ns1:DiseaseOrFinding ;
    ns1:description "A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)     "@en ;
    ns1:title "Leukemie"@cs,
        "Leukemia"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000001905> a ns1:DiseaseOrFinding ;
    ns1:description "A general term for various neoplastic diseases of the lymphoid tissue.     "@en ;
    ns1:title "Lymfom"@cs,
        "Lymphoma"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000001978> a ns1:DiseaseOrFinding ;
    ns1:description "Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.     "@en ;
    ns1:title "Meningy - nádory"@cs,
        "Meningeal neoplasms"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000003261> a ns1:DiseaseOrFinding ;
    ns1:description "Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.     "@en ;
    ns1:title "Chronická myeloidní leukemie"@cs,
        "Leukemia, myelogenous, chronic, bcr-abl positive"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000003565> a ns1:DiseaseOrFinding ;
    ns1:description "A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.     "@en ;
    ns1:title "Leukemická infiltrace"@cs,
        "Leukemic infiltration"@en .

<http://linked.opendata.cz/resource/ndfrt/disease/N0000010195> a ns1:DiseaseOrFinding ;
    ns1:description "The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.     "@en ;
    ns1:title "Těhotenství"@cs,
        "Pregnancy"@en .

<http://linked.opendata.cz/resource/ndfrt/mechanism-of-action/N0000000233> a ns1:MechanismOfAction ;
    ns1:title "Nucleic Acid Synthesis Inhibitors"@en .

<http://linked.opendata.cz/resource/ndfrt/physiologic-effect/N0000008576> a ns1:PhysiologicEffect ;
    ns1:title "Decreased DNA Integrity"@en .

<http://linked.opendata.cz/resource/sukl/medicinal-product/ALEXAN-50-MG-ML> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "ALEXAN 50 MG/ML"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/CYTARABIN-KABI-100-MG-ML> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "CYTARABIN KABI 100 MG/ML"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-1-G> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "CYTOSAR 1 G"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-100-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "CYTOSAR 100 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/CYTOSAR-500-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "CYTOSAR 500 MG"@cs .

<http://linked.opendata.cz/resource/sukl/medicinal-product/DEPOCYTE-50-MG> a ns1:MedicinalProduct ;
    ns1:hasATCConcept "http://linked.opendata.cz/resource/ATC/L01BC01" ;
    ns1:title "DEPOCYTE 50 MG"@cs .


